TCGA-P3-A6T3-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.13173516
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.390
- HYPOXIA+0.360
- MYC_TARGETS_V1+0.330
- TGF_BETA_SIGNALING+0.290
- ANDROGEN_RESPONSE+0.240
- P53_PATHWAY+0.240
- PROTEIN_SECRETION+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.230
- GLYCOLYSIS+0.220
- CHOLESTEROL_HOMEOSTASIS+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.360
- E2F_TARGETS-0.350
- INTERFERON_GAMMA_RESPONSE-0.290
- G2M_CHECKPOINT-0.220
- BILE_ACID_METABOLISM-0.200
- ADIPOGENESIS-0.170
- KRAS_SIGNALING_DN-0.160
- SPERMATOGENESIS-0.130
- OXIDATIVE_PHOSPHORYLATION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KP735TJ6 | high-grade glioma | — | 0.866 |
| 2 | ERR2278862 | — | — | 0.789 |
| 3 | SRR5088827 | — | — | 0.771 |
| 4 | eaecaea1-2cb7-472c-b549-ff779e5e1d30 | — | — | 0.755 |
| 5 | SRR6079987 | — | — | 0.750 |
| 6 | MNG20 | — | — | 0.733 |
| 7 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.732 |
| 8 | TCGA-FT-A3EE-01A-11R-A206-07 | — | — | 0.713 |
| 9 | SRR10842375 | — | — | 0.707 |
| 10 | SRR1313119 | — | A | 0.692 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |